^
Association details:
Evidence:
Evidence Level:
Resistant: A2 - Guideline
New
Source:
Title:

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Excerpt:
In particular, V299L, T315A and F317L/V/I/C are resistant to dasatinib. Y253H, E255K/V and F359V/C/I are resistant to nilotinib, and V299L to bosutinib.
DOI:
10.1093/annonc/mdx219
Evidence Level:
Resistant: A2 - Guideline
New
Source:
Excerpt:
Treatment recommendations based on BCR-ABL1 mutation profile...The table below lists the BCR-ABL1 mutations that should not be treated with bosutinib, dasatinib or nilotinib in the second-line setting...Nilotinib…T315I, Y253H, E255K/V, or F359V/C/I or G250E
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Excerpt:
Patients with mutations that were less sensitive to nilotinib in vitro (IC(50) > 150 nM; Y253H, E255V/K, F359V/C) had less favorable responses, as 13%, 43%, and 9% of patients with each of these mutations, respectively, achieved MCyR; none achieved CCyR. The most common mutations associated with progression were the E255K/V, F359C/V, Y253H, and T315I mutations.
DOI:
10.1200/JCO.2009.21.8230